Inhibidor de TRPC6: El Resumen Visual

Por primera vez, una terapia dirigida al podocito muestra eficacia clínica en GEFyS. Esta semana #NephJC revisa el ECA fase 2 de BI 764198, inhibidor oral de TRPC6, que redujo proteinuria, estabilizó el FGe y fue bien tolerado. ¿El inicio de una nueva era en GEFyS? Revisa el resumen visual por la Dra Divya Bajpai

View fullsize

TRPC6 inhibition: The Visual Abstract

For the first time, a podocyte-targeted therapy shows clinical efficacy in FSGS. This week #NephJC covers the phase 2 RCT of BI 764198, an oral TRPC6 inhibitor that lowered proteinuria, preserved eGFR, and was well tolerated. A new era in FSGS? Check out the visual abstract by Divya Bajpai

View fullsize

Can hydralazine trigger ANCA vasculitis?

A large registry cohort was essential to move beyond scattered case reports and finally quantify the true risk of hydralazine‑associated vasculitis. When rare events blur into background noise, only scale can clarify the signal. Can population‑level data sharpen the picture?

Check out Divya Bajpai VA

View fullsize

¿Puede la hidralazina desencadenar vasculitis ANCA? El resumen visual

Un gran registro poblacional era esencial para superar décadas de reportes aislados y cuantificar por fin el riesgo real de la vasculitis asociada a hidralazina. Cuando los eventos raros se confunden con el ruido de fondo, solo la escala permite distinguir la señal. ¿Puede la evidencia a nivel poblacional aclarar por fin este panorama?

Revisa el resumen visual por Divya Bajpai , traducir por Milagros Flores

Regarding the Situation with…Social Media in General

Regarding the Situation with…Twitter, Bluesky, Social Media

We at #NephJC pride ourselves on bringing you the best in nephrology publications and innovations without commercial bias. As we’ve stated during many a donation drive, we are beholden to none but our followers and readers.

Having said that, we’ve noticed a trend since the death of Twitter (yes, it will always be Twitter to the real FOAMed illuminati). The diaspora of NephTwitter were scattered throughout the nephro-universe of social media, never quite finding a new home. Perhaps the downfall of the Nephrologians can be a plot line for the next Mandalorian season?? Many left the social media space altogether because of the division, politicization and plain BS of some of the algorithms (I for one don’t need to see EVERYTHING Elon posts). However, we still believe there is a need for our unique style of nephrology education. Jon Stewart- yes, the comedian- recently likened social media to smoking: an addictive, attention seeking habit that is generally recognized as not healthy for most people and that is likely to be regulated for teen and self-regulate by adults. He believed the antidote was more long-form, nuanced edu-tainment. So, it light of the changing landscape, we are going to focus more on our blogs, VAs, and podcasts and less on live discussions on Bluesky.

NephJC is nothing if not nimble, and we have never been afraid of change.

So, given the low attendance at live chats (no judgement) we’re changing to a summary thread (a new 10 posts) with provocative questions to answer, at your leisure. We hope this keeps the discussions going without the need to be on social media for prolonged periods or at a specific hour and day. These threads will be posted at the familiar 9pm EST every other Tuesday. This shorter form will also allow us to post on multiple sites, and hopefully we will be easily accessible to you where you chat with other nephrophiles. Feel free to reply, chat, tag people in conversations whenever and wherever you see a #NephJC post. The team will be around, but we won’t be actively ‘moderating’ a one hour chat.

Sincerely,

NephJC Leadership

PS: As always we love to hear from our audience. If you have suggestions, or a better way to reach more people, we are all ears. Heck, if we hear enough complaints we might even bring back the chats!😉

Hiponatremia: El Resumen Visual

La hiponatremia es uno de los trastornos electrolíticos más frecuentes en pacientes hospitalizados y se asocia de manera consistente con peores desenlaces. Su corrección mejora los valores, pero ¿realmente mejora los desenlaces clínicos ?

Revisa el resumen visual por Brian Rifkin y el nuevo formato de #NephJC

Hyponatremia Correction: The Visual Abstract

Hyponatremia is one of the most common electrolyte disorders in hospitalized patients and is consistently linked to worse outcomes. Correcting sodium improves the numbers—but does it improve short-term clinical outcomes?

Check out Brian Rifkin VA and the new #NephJC format

Announcing the NephJC Editorial Internship

Are you a curious, motivated nephrology fellow or early‑career faculty member with a passion for science communication? NephJC is inviting a small group of talented individuals to join our Editorial Internship Program and become part of the team that shapes how nephrology is discussed, illustrated, and shared online.

As an intern, you’ll help craft the bimonthly NephJC Journal Club, one of the most vibrant hubs for post‑publication peer review in nephrology, while developing your skills as an editor, writer, illustrator, or podcaster. We’re also planning to expand our Instagram presence this year, so creative voices with an eye for visual storytelling will have new opportunities to shine.

What this internship offers

• Collaboration with an experienced, dynamic production team

• Engagement with cutting‑edge nephrology research

• Increased professional visibility within the global nephrology community

Take your passion for kidneys, curiosity, and community to the next level- join the NephJC Editorial Internship Program and help us keep the nephrology spirit alive across platforms, including a more active IG presence.

TenPosts Rilparencel phase 2

Can we move beyond slowing CKD to actually repairing the kidney? Here is the summary of the last #NephJC chat discussing Rilparencel, a renal autologous cell therapy (REACT) infusion, and its effect on eGFR slope.
Thread by Akshaya Jayachandran